Boston scientific launches next generation of cardiac mapping for the farapulse™ pulsed field ablation system

New farawave™ nav ablation catheter and faraview™ software combine with opal hdx™ mapping system to provide visualization during pulsed field ablation marlborough, mass. , oct. 18, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has received u.s. food and drug administration (fda) approval for the navigation-enabled farawave™ nav ablation catheter for the treatment of paroxysmal atrial fibrillation (af) and fda 510(k) clearance for the new faraview™ software, which will combine to provide visualization for cardiac ablation procedures with the farapulse™ pulsed field ablation (pfa) system.
BSX Ratings Summary
BSX Quant Ranking